|
DuPont submitted a letter to the New Jersey Department of Environmental Protection reporting that initial analytical results for perfluorooctanoate (PFOA) from the Penns Grove Water Supply Company were significantly below established regulatory guidance for drinking water.
|
2006 |
AR226-3660
|
xzG4LwD4OnaQMzeyvqm2ZMx5E |
3 |
|
This document reports the results of a 28-day immunotoxicity study conducted by DuPont on Ammonium Perfluorooctanoate (APFO-linear), indicating that the study was negative for immunosuppression in rats, while some immune-related findings were observed in mice.
|
2006 |
AR226-3662
|
a1YyyJ8MRjVkOV27Dz5GOK6B |
6 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice to the EPA, providing analytical summary sheets from the Minnesota Pollution Control Agency regarding fluorochemical analyses in fish samples from the Mississippi River, while clarifying that they did not participate in the sampling or analysis.
|
2006 |
AR226-3663
|
2jOzO2rxkdm1oK0Yz6BKEgGKR |
3 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice to the EPA, providing analytical summary sheets from the Minnesota Pollution Control Agency regarding fluorochemical analyses in fish samples from the Mississippi River, while clarifying that 3M did not participate in the sampling or analysis.
|
2006 |
AR226-3664
|
MobgGM2mV0pdbYBNKQyrzMZGM |
3 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice to the EPA regarding a pilot study that found a 50% decline in serum concentrations of PFOS and PFOA among American Red Cross blood donors in 2005 compared to measurements from 2000, while asserting that these findings do not indicate a substantial risk to health or the environment.
|
2006 |
AR226-3665
|
Y99dE44rmoBoDX3bYqv9v2e2K |
1 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice to the EPA regarding a pilot study that found a 50% decline in serum concentrations of PFOS and PFOA among American Red Cross blood donors in 2005 compared to measurements from 2000, while asserting that these findings do not indicate a substantial risk to health or the environment.
|
2006 |
AR226-3667
|
nkmgk1gJ5bdbeN5NZrEb3Zp4w |
1 |
|
This document is a final report from a pilot study conducted by 3M Company to assess serum concentrations of PFOS and PFOA in American Red Cross blood donors in 2005, aiming to determine if these concentrations represent a decline from prior measurements made in 2000.
|
2006 |
AR226-3666
|
yk6ndjMN4L7OyYzmry0K7x7Kr |
20 |
|
The document is a final report from 3M Company detailing a pilot study conducted in 2005 to assess serum concentrations of PFOS and PFOA in American Red Cross blood donors, aiming to determine if these concentrations had declined compared to measurements from 2000.
|
2006 |
AR226-3668
|
N2rmwDROLvbMg4ZnrMw5qQJXQ |
20 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice to the EPA regarding a pilot study that found a 50% decline in serum concentrations of PFOS and PFOA among American Red Cross blood donors in 2005 compared to measurements from 2000, while asserting that these findings do not indicate a substantial risk to health or the environment.
|
2006 |
AR226-3669
|
91a3djR1GJgL8D3kXBDqjy8yR |
1 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice to the EPA, providing analytical summary sheets from the Minnesota Pollution Control Agency regarding fluorochemical analyses in fish samples from the Mississippi River, while clarifying that they did not participate in the sampling or analysis.
|
2006 |
AR226-3671
|
mm6BYda7GBBNe3yOL44Nrz88Q |
3 |
|
The document is a final report from a pilot study conducted by 3M Company to assess serum concentrations of PFOS and PFOA in American Red Cross blood donors in 2005, aiming to determine if these levels represent a decline compared to measurements from 2000.
|
2006 |
AR226-3670
|
2qYa1QRxnQ30VkM208z852gaa |
20 |
|
Preliminary data from a 3M-sponsored study indicate that perfluorooctanesulfonate (PFOS) and perfluorohexanesulfonate (PFHS) affect body weight, food consumption, and serum cholesterol in transgenic mice, with notable reductions observed at specific dietary concentrations.
|
2006 |
AR226-3672
|
r6BQJyNawpLGk3xe5gx0Xd39J |
1 |
|
Preliminary data from a 3M-sponsored study indicates that perfluorooctanesulfonate (PFOS) and perfluorohexanesulfonate (PFHS) affect body weight, food consumption, and serum cholesterol in transgenic mice, with observed reductions in cholesterol and body weight at specific dietary concentrations.
|
2006 |
AR226-3673
|
LBQ89GrprOonjZwoRj0L7JR3 |
1 |
|
Preliminary data from a 3M-sponsored study indicate that perfluorooctanesulfonate (PFOS) and perfluorohexanesulfonate (PFHS) affect body weight, food consumption, and serum cholesterol in E3 Leiden transgenic mice, with notable reductions observed at specific dietary concentrations.
|
2006 |
AR226-3674
|
6bo5mp1axonDQJV4EE5Nx1BKE |
3 |
|
3M submitted data on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and related compounds, including three studies on serum fluorochemical concentrations, medical conditions in manufacturing workers, and a medical surveillance program at their facilities.
|
2006 |
AR226-3675
|
30LoXmaEkOVexkjgg700V9bx |
2 |
|
This document is a final report from 3M Company detailing a pilot study conducted in 2005 to assess serum concentrations of PFOS and PFOA in American Red Cross blood donors, aiming to determine if these concentrations had declined compared to measurements from 2000.
|
2006 |
AR226-3676
|
embzygk0o7BvMVNxMyZ0NZG74 |
20 |
|
The report investigates the relationship between self-reported health conditions, including cancers, among employees at a 3M facility in Decatur, Alabama, and their exposure to perfluorooctanesulfonyl fluoride (POSF) and perfluorooctanesulfonate (PFOS), focusing on potential links to bladder cancer and other health issues.
|
2006 |
AR226-3677
|
mpKJxoZXK7BDZEM235ErG851B |
26 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice to the EPA detailing the results of environmental assessments for PFOA, PFOS, PFHS, and PFBS in groundwater, sediments, surface water, fish, and clams near its Decatur, Alabama manufacturing facility.
|
2006 |
AR226-3680
|
RppoOX3r8KonVm71avQdzJQvE |
2 |
|
The document is a final report from 3M Company analyzing the 2000 medical surveillance program for perfluorooctanoate (PFOA) among workers at their facilities in Antwerp, Cottage Grove, and Decatur, noting no consistent associations with clinical chemistry measurements, although a weak positive association with total cholesterol was observed but deemed spurious.
|
2006 |
AR226-3678
|
yp7Bm9OGEvwVZ05G2gVOZnzGr |
170 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice to the EPA, providing analytical results for PFOA, PFOS, PFHS, and PFBS from groundwater, sediments, surface water, fish, and clams near its Decatur, Alabama manufacturing facility as part of an environmental assessment.
|
2006 |
AR226-3685
|
ypzM8Xk8zVzvEYbE8L84p19Nn |
2 |
|
The document is an interim report from Exygen Research analyzing sediment samples for Perfluorooctanoic Acid (PFOA) as part of the 3M Decatur Monitoring Program, conducted in compliance with EPA TSCA Good Laboratory Practice Standards.
|
2006 |
AR226-3682
|
YBMkK54R8wm3eEk778EVQbeV |
110 |
|
The document is a report by DuPont researchers on the environmental fate of Perfluorooctanoic Acid (PFOA), detailing its physical-chemical properties, persistence, and biodegradation.
|
2006 |
AR226-3679
|
QRbyO35nGaQO9LMnDMoMMZLk |
154 |
|
This interim report details the analysis of Perfluorobutanesulfonate (PFBS), Perfluorohexanesulfonate (PFHS), and Perfluorooctanesulfonate (PFOS) in various environmental samples as part of the 3M Decatur Monitoring Program, conducted by Exygen Research under Good Laboratory Practice standards.
|
2006 |
AR226-3683
|
zdjgR9q0R95aXkKGBpNbaKNq6 |
110 |
|
This document is an interim report detailing the analysis of Perfluorooctanoic Acid (PFOA) in various environmental samples for the 3M Decatur Monitoring Program, conducted by Exygen Research in compliance with EPA TSCA Good Laboratory Practice Standards, with a noted exception regarding control recording.
|
2006 |
AR226-3687
|
r66KMy6yMpvZbYOagwvEzy0ge |
110 |
|
This interim report details the analysis of perfluorobutanesulfonate (PFBS), perfluorohexanesulfonate (PFHS), and perfluorooctanesulfonate (PFOS) in various environmental samples as part of the 3M Decatur Monitoring Program, conducted by Exygen Research in compliance with EPA TSCA Good Laboratory Practice Standards.
|
2006 |
AR226-3684
|
0qrqDR6KLmbjg610E1XnzyeBd |
131 |
|
This interim report details the analysis of Perfluorobutanesulfonate (PFBS), Perfluorohexanesulfonate (PFHS), and Perfluorooctanesulfonate (PFOS) in various environmental samples for the 3M Decatur Monitoring Program, conducted by Exygen Research under EPA TSCA Good Laboratory Practice Standards, with a noted exception regarding
|
2006 |
AR226-3688
|
M499dZeJgzQzabZNdaJ4pJdRV |
111 |
|
3M submitted a supplemental notice to the EPA regarding analytical data for water samples from municipal wells in Oakdale, Minnesota, specifically reporting on the presence of PFOA, PFOS, and other fluorochemicals, while stating that they do not believe the data indicates a "substantial risk" under TSCA Section 8(e).
|
2006 |
AR226-3690
|
pmMp7a3Nw809mDLZ3JjpbDm5B |
2 |
|
The document reports on the distribution of PFOA, PFOS, and PFBA concentrations in private and city wells as well as surface water, indicating that no results were available for June 2006.
|
2006 |
AR226-3693
|
dngK3EXb2prE10K1qOMEnnnY9 |
5 |
|
This interim report details the analysis of Perfluorobutanesulfonate (PFBS), Perfluorohexanesulfonate (PFHS), and Perfluorooctanesulfonate (PFOS) in various environmental samples for the 3M Decatur Monitoring Program, conducted by Exygen Research in compliance with EPA TSCA Good Laboratory Practice Standards.
|
2006 |
AR226-3689
|
dEdm0NVoQexj9Enb9na4zOGB |
132 |
|
The document reports on a consultation meeting held by Environment Canada and Health Canada regarding the proposed action plan for perfluorocarboxylic acids (PFCAs) and their precursors, discussing scientific and regulatory contexts, feedback on proposed actions for both new and existing substances, and next steps in the process.
|
2006 |
AR226-3696
|
X7G6G7JRLkw3pa9n9q16ydpYR |
27 |
|
The document is a correspondence regarding a PFOA worker exposure health effects study, responding to requests for information from the EPA and other governmental entities.
|
2006 |
AR226-3697
|
zQnOydB66eK0gye6qEZXYyjXg |
9 |
|
This document is a correspondence from Taft, Stettinius & Hollister LLP regarding the submission of human health data related to perfluorochemicals, specifically addressing requests from the EPA and other entities concerning potential threats to human health and the environment.
|
2006 |
AR226-3698
|
3909eYL9VVZYGDVmKgZR80py |
3 |
|
This document is a Minnesota Department of Health health alert from April 3, 2006, regarding respiratory illnesses linked to aerosolized waterproofing products, prompting an advisory for Michigan hospitals and urging physicians to report cases to poison control centers.
|
2006 |
AR226-3700
|
ymnLwQjJB01zp77bLY5KoDya2 |
1 |
|
The Central Ohio Poison Center at Columbus Children's Hospital is warning consumers about potential respiratory illnesses linked to boot leather protector and sealant products, particularly "Jobsite Heavy Duty Bootmate," following over 250 reports of symptoms such as coughing and shortness of breath.
|
2006 |
AR226-3701
|
M4JdJD22qo53kqBko67aYqBEa |
1 |
|
The Kentucky Department for Public Health issued a warning about the health risks associated with indoor use of spray-on waterproofing products, particularly those under the "Bootmate" brand, after receiving reports of 149 illnesses, including respiratory symptoms, linked to their use.
|
2006 |
AR226-3702
|
XR80pkMxEEy0V03XVrjBdJQXy |
1 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice indicating that PFOS and PFOA were detected in groundwater samples from five wells and the water distribution system at its Cordova, Illinois plant, with concentrations ranging from 0.16 to 12 ppb for PFOS and 0.22 to 4.6 ppb for PFOA, and has notified employees
|
2006 |
AR226-3715
|
2j0DgGJgOr1Rabb196VBQZga6 |
1 |
|
This document is a submission from 3M to the EPA detailing the fourth set of monitoring data for perfluorooctanoic acid (PFOA) from groundwater and wastewater at their manufacturing sites in Cottage Grove, MN, and Decatur, AL, as part of their commitments following the production phase-out of PFOA completed in 2002.
|
2006 |
AR226-3714
|
O37xpkpM6kvXvyvyjZLzVe2e1 |
10 |
|
This is a DuPont document related to PFOA, dated September 15, 2006, containing metadata but no analytical content retained in the OCR.
|
2006 |
AR226-3717
|
6b9kkmbQkGEJvNBaxZ412ML76 |
2 |
|
Daikin America Inc. submitted baseline information on PFOA levels in their products and facility releases as part of their commitment to the EPA's PFOA Stewardship Program, aiming for significant reductions by 2010 and working towards the elimination of PFOA by 2015.
|
2006 |
AR226-3719
|
a18RJamwRLOoNdde1856JOD7R |
2 |
|
3M submitted a TSCA 8(e) Substantial Risk Notice to the EPA, providing supplemental analytical reports on PFOA from their Decatur, Alabama site monitoring assessment, detailing findings from soil, water, sludge, and sediment samples.
|
2006 |
AR226-3721
|
7R0yy1eZdN1xwVqL5EeZGNQM6 |
1 |
|
The document presents off-site sampling results for PFOA concentrations in soil and groundwater near the 3M Decatur facility in Alabama, indicating various levels of contamination with some samples reporting concentrations as high as 311.5 ppb.
|
2006 |
AR226-3722
|
YG7xJBdbK6OqVzN89XV4a11Xk |
2 |
|
3M is submitting a TSCA 8(e) Substantial Risk Notice to the EPA regarding the analysis of PFOA, PFOS, PFHS, and PFBS in groundwater, sediments, surface water, fish, and clams near its Decatur, Alabama manufacturing facility as part of an environmental assessment.
|
2006 |
AR226-3725
|
4aNmbBX9pbyrGok0EQ0LK0BxG |
2 |
|
This interim report details the analysis of Perfluorooctanoic Acid (PFOA) in various environmental samples as part of the 3M Decatur Monitoring Program, conducted by Exygen Research in compliance with EPA TSCA Good Laboratory Practice Standards.
|
2006 |
AR226-3723
|
7RN7gjrQ5EdXpMGxENaZ8GbD6 |
151 |
|
This interim report details the analysis of Perfluorooctanoic Acid (PFOA) in various environmental samples as part of the 3M Decatur Monitoring Program, conducted by Exygen Research and compliant with EPA TSCA Good Laboratory Practice Standards, with a noted exception regarding documentation of laboratory controls.
|
2006 |
AR226-3727
|
zQbRD7mdE0gNpkrdRG0nGwkJz |
110 |
|
The document is an interim report detailing the analysis of Perfluorobutanesulfonate (PFBS), Perfluorohexanesulfonate (PFHS), and Perfluorooctanesulfonate (PFOS) in various environmental samples for the 3M Decatur Monitoring Program, conducted by Exygen Research in compliance with EPA TSCA Good Laboratory Practice Standards.
|
2006 |
AR226-3728
|
ykp7z0X1p9Ge1rw7dXGjkNR6r |
110 |
|
The document is a report from Daikin America, Inc. submitted to the EPA detailing the material balance of Perfluorooctanoic Acid (PFOA) for their Decatur Plant in 2005, including a comparison to data from 2000.
|
2006 |
AR226-3730
|
3QpjLY5mEbgOaMQbnREvOqNBD |
2 |
|
The document discusses a submission by 3M to the EPA regarding a follow-up study on health conditions, specifically bladder cancer and other health endpoints, among workers at a perfluorooctanesulfonyl fluoride (POSF)-based fluorochemical manufacturing facility, including a report from the University of Minnesota on self-reported medical conditions.
|
2006 |
AR226-3731
|
V36J8MRxrZKkYanvB7zO868YK |
2 |
|
The document is an interim report from Exygen Research detailing the analysis of perfluorobutanesulfonate (PFBS), perfluorohexanesulfonate (PFHS), and perfluorooctanesulfonate (PFOS) in various environmental samples for the 3M Decatur Monitoring Program, conducted in compliance with EPA TSCA Good Laboratory Practice Standards.
|
2006 |
AR226-3729
|
jB5Yr2e3oMoe901OLDN8Ljexp |
132 |
|
The document is a final report on a health study investigating self-reported medical conditions, including cancers, among employees at a 3M facility in Decatur, Alabama, potentially linked to exposure to perfluorooctanesulfonyl fluoride (POSF) and perfluorooctanesulfonate (PFOS).
|
2006 |
AR226-3732
|
NmgD2dDOJeB6vD1key8XLq78 |
26 |
|
DuPont submitted updated occupational blood monitoring information for Perfluorooctanoic Acid (PFOA) to the EPA, reporting that serum sample results from Axys Analytical Services corroborated previously reported levels, with PFOA concentrations ranging from 7.71 ng/mL to 2630 ng/mL and consistent results within 20% of those from Exygen Laboratories.
|
2006 |
AR226-3733
|
pBJ8L9VLg6BvoMEyQzgm9V58j |
3 |
|
This document contains analytical results from various DuPont facilities regarding the detection and quantification of multiple perfluorinated compounds, including PFOA and PFOS, with specific recovery percentages and concentration levels reported for each compound.
|
2006 |
AR226-3734
|
Lk8ewDrLE8ek2mDDv860GnBb |
4 |
|
This is an analytical report from Axys Analytical Services detailing the results of perfluorinated compounds analysis in serum samples, with associated job numbers and extraction data.
|
2006 |
AR226-3735
|
Lp2dZqxGJvqY4ZNxgyQGDENw |
3 |
|
DuPont has submitted preliminary partial non-occupational blood data related to perfluorooctanoic acid (PFOA) collected from communities in West Virginia and Ohio to the EPA, as part of a class action settlement concerning PFOA releases from its facility, while noting that it lacks access to the complete data set.
|
2006 |
AR226-3736
|
8O7BqZ4pVZjw88G73DjnRwoKd |
3 |
|
The document outlines preliminary protocols for a health study on the effects of exposure to C8 (PFOA) around the Washington Works plant, emphasizing that certain confidential data should not be disclosed to the public and that the preliminary findings are not suitable for drawing health conclusions.
|
2006 |
AR226-3737
|
Qk3nKgdwX7ROQxyoNnwQ5ry67 |
1 |
|
This document presents statistical data on C8 (PFOA) blood levels among a community cohort in 2005, detailing demographics, body mass index, and anticipated distribution of C8 levels in participants, with mean and median levels reported at 130 ppb and 48 ppb, respectively.
|
2006 |
AR226-3738
|
jNj7jg3wb49JOqrDQbmVVEyO2 |
6 |
|
The document presents preliminary analyses of pregnancy outcomes among women exposed to perfluorinated compounds, detailing miscarriage, stillbirth, preterm birth, low birth weight, and birth defects, while also discussing statistical power calculations for detecting significant results in future studies.
|
2006 |
AR226-3740
|
wDpeJjxEaJaedkpg0E4npyngD |
3 |
|
This document is a submission from DuPont's legal counsel, Andrea V. Malinowski, to the EPA regarding a baseline study/report on PFOA and PFOS sampling conducted in Pascagoula, Mississippi, which has also been provided to state environmental agencies.
|
2006 |
AR226-3741
|
o929x4OYQGNdKzdLmvEqMKd9E |
1 |
|
This document provides updated serum sampling results for perfluorooctanoic acid (PFOA) from employees at the First Chemical Corporation in Pascagoula, Mississippi, indicating that PFOA levels in 2006 are consistent with those found in 2003 and comparable to levels in the general population.
|
2006 |
AR226-3745
|
kD5DnqXq39ZjZzReRJa7m8460 |
2 |
|
A retrospective exposure analysis estimated potential residential exposure to perfluorooctanoic acid (PFOA) from a manufacturing facility in Ohio and West Virginia, identifying air emissions and soil transfer as the primary sources of PFOA contamination in groundwater over a 53-year period.
|
2006 |
AR226-3744
|
LJywD01YJnn2vaXyzOBvKpKw5 |
11 |
|
The Pascagoula Baseline Study/Report for First Chemical Corporation details the sampling and analysis of water and solids in Pascagoula, Mississippi, focusing on the occurrence of PFOA and PFOS in various environmental matrices.
|
2006 |
AR226-3742
|
xza82ngRp4D83OKO781xo3nNQ |
40 |
|
The document presents employee blood serum results from First Chemical Corporation in Pascagoula, Mississippi, comparing PFOA levels from baseline samples taken in December 2003 to those taken in August 2006, highlighting variations in average and maximum concentrations among workers.
|
2006 |
AR226-3746
|
rpYdx0mdxQ4DjkOJ2bKE0rkRr |
3 |
|
DuPont First Chemical's blood monitoring program for PFOA levels in employee volunteers showed that average exposure levels increased from 5.9 ppb in 2003 to 7.9 ppb in 2006, which are consistent with general population background levels and not indicative of occupational exposure.
|
2006 |
AR226-3747
|
93eopK4gVm67L5GObwXvd2QyV |
3 |
|
DuPont submitted a document to the EPA containing analytical results for perfluorinated organics, specifically from a report by Axys Analytical Services requested by the Little Hocking Water Association, but DuPont does not verify the validity of the results.
|
2006 |
AR226-3581
|
JvBz6rGvaeeRxJOp4KJMmndGO |
8 |
|
DuPont submitted a follow-up letter to the EPA regarding an oral repeated dose toxicity study in rats and mice involving linear and branched forms of perfluorooctanoic acid (APFO), along with the final report of the study.
|
2006 |
AR226-3582
|
rXKJDw1n1eLkap35a260zaoE |
2 |
|
The document is a report from Daikin America, Inc. submitted to the EPA detailing the material balance of Perfluorooctanoic Acid (PFOA) for their Decatur Plant in 2005, including a comparison to data from 2000.
|
2006 |
AR226-3730
|
L2eE438p1E0mD54z5OaOOKqX |
2 |
|
3M submitted additional information to the EPA regarding a health study on perfluorooctanesulfonyl fluoride (POSF) manufacturing workers, which included a report on self-reported medical conditions and confirmed that there was no excess incidence of bladder cancer among the workers, despite previous findings of excess bladder cancer mortality.
|
2006 |
AR226-3731
|
rxmqvE9EwQjqoEOkk0brzXoGV |
2 |
|
DuPont submitted updated occupational blood monitoring information for Perfluorooctanoic Acid (PFOA) to the EPA, reporting that serum sample results from Axys Analytical Services ranged from 7.71 ng/mL to 2630 ng/mL and were consistent with previous findings from Exygen Laboratories.
|
2006 |
AR226-3733
|
ZJxLj7z8KjVVD6oQNZanGDnzd |
3 |
|
This document consists of analytical reports from Axys Analytical Services detailing the analysis of serum samples for various perfluorinated compounds, including PFOA, with associated contract and sample information.
|
2006 |
AR226-3735
|
EOy8ZMNRpEZv9E3vqMDQ2g7L |
3 |
|
This document contains analytical results for various perfluorinated compounds, including PFOA and PFOS, from samples collected at DuPont facilities, detailing recovery rates and concentrations measured in nanograms per milliliter.
|
2006 |
AR226-3734
|
jm5v0kRxZnepBn7944Ev4anBO |
4 |
|
The document is a final report on a health study investigating the relationship between self-reported medical conditions, including cancers, and employment at a perfluorooctanesulfonyl fluoride (POSF) production facility, specifically focusing on PFOS exposure among workers at the 3M facility in Decatur, Alabama.
|
2006 |
AR226-3732
|
a4xZqZgNnMoyJ0Zq6eELxXmQX |
26 |
|
DuPont provided preliminary partial non-occupational blood data on perfluorooctanoic acid (PFOA) collected from communities in West Virginia and Ohio to the EPA, acknowledging that they do not have access to the complete dataset from Brookmar, which is conducting the study independently.
|
2006 |
AR226-3736
|
vVNXr44yORbjpaD7RrxwXmErm |
3 |
|
The document outlines preliminary protocols for a health study on the effects of exposure to C8 (PFOA) around the Washington Works plant, emphasizing the confidentiality of initial data received from Brookmar and cautioning against drawing conclusions from it.
|
2006 |
AR226-3737
|
k9Eqvdk1omMZZ2Q2mp1ZJ6vKb |
1 |
|
The document presents statistical data on C8 (PFOA) blood levels among a community cohort of 23,942 participants aged 20 and older, detailing mean and median levels, demographic information, and distribution across different water districts in relation to drinking water sources.
|
2006 |
AR226-3738
|
2jzbD0kbJa8pokBR3rEz562LR |
6 |
|
The document is a submission from DuPont's legal counsel, Andrea V. Malinowski, to the EPA regarding a baseline study/report on PFOA and PFOS conducted in Pascagoula, Mississippi, which has also been provided to state environmental agencies.
|
2006 |
AR226-3741
|
2qEV5YR2jdNVoDzYLkvXL5gmg |
1 |
|
The document presents preliminary analyses of pregnancy outcomes among women, including miscarriage and birth defect rates, in relation to potential exposure to perfluorinated compounds, specifically focusing on data from a study involving 18,276 women and 48,007 pregnancies.
|
2006 |
AR226-3740
|
jmeem206B4B6m7aEnLx6ZrzJ2 |
3 |
|
This document is a report from Daikin America, Inc. submitted to the EPA detailing the material balance of Perfluorooctanoic Acid (PFOA) for their Decatur Plant in 2005, including a comparison to data from 2000.
|
2006 |
AR226-3730
|
MG6Xga5x53XDOn054o5X8YgQ9 |
2 |
|
This document is a submission by 3M to the EPA regarding additional information on a mortality study and subsequent health incidence study related to perfluorooctanesulfonyl fluoride (POSF) manufacturing workers, highlighting a final report on self-reported medical conditions that examined various health endpoints, including cancer.
|
2006 |
AR226-3731
|
Gmnw9OZN30dVzvyzDzXMrjadv |
2 |
|
DuPont submitted updated occupational blood monitoring information for Perfluorooctanoic Acid (PFOA) to the EPA, reporting serum sample results from Axys Analytical Services that corroborate previous findings, with PFOA levels ranging from 7.71 ng/mL to 2630 ng/mL and consistent results within 20% of those reported by Exygen Laboratories.
|
2006 |
AR226-3733
|
dnpZV5rkK75wBxqxKzk4DNrGQ |
3 |
|
The Pascagoula Baseline Study/Report for First Chemical Corporation details the sampling and analysis of water and solids in Pascagoula, Mississippi, focusing on the occurrence of PFOA and PFOS, with findings related to their presence in surface water, groundwater, and sludge.
|
2006 |
AR226-3742
|
DGwvG99g2Dzgb0rrN8ayvx85 |
40 |
|
The document contains analytical results from various DuPont facilities regarding the detection and quantification of perfluorinated compounds, including PFOA and PFOS, with specific recovery rates and concentration measurements.
|
2006 |
AR226-3734
|
mmokap5Q7yLaYpjQj7LXvGp4k |
4 |
|
The document is a final report on a health study investigating the relationship between self-reported medical conditions, including cancers, and employment at a perfluorooctanesulfonyl fluoride (POSF) production facility, specifically focusing on PFOS exposure among workers at the 3M facility in Decatur, Alabama.
|
2006 |
AR226-3732
|
ba2em1xkZ6mY178bDdvR469Yg |
26 |
|
This is an analytical report from Axys Analytical Services detailing the results of perfluorinated compounds analysis in serum samples, with sample receipt dated February 20, 2006, and analysis conducted on March 30, 2006.
|
2006 |
AR226-3735
|
ZBDOYQDQNJBkxJxxxyZY6Z0BJ |
3 |
|
DuPont submitted preliminary partial non-occupational blood data related to perfluorooctanoic acid (PFOA) collected from communities in West Virginia and Ohio to the EPA, highlighting that the data is incomplete and derived from a study not directed by DuPont.
|
2006 |
AR226-3736
|
71J9Q2LdrDw1LLj3yV2DZVo9j |
3 |
|
This document is a submission by 3M to the EPA regarding additional information on a mortality study and subsequent health incidence study of workers at a perfluorooctanesulfonyl fluoride (POSF)-based fluorochemical manufacturing facility, highlighting findings related to bladder cancer and other health conditions reported by workers.
|
2006 |
AR226-3731
|
G6yjvQOvEQB0V3woN5O66x6V |
2 |
|
This document is a report from Daikin America, Inc. submitted to the EPA detailing the material balance of Perfluorooctanoic Acid (PFOA) for their Decatur Plant in 2005, including a comparison to the year 2000.
|
2006 |
AR226-3730
|
LKGNJe21g4vRDKKwLDGkeZGn7 |
2 |
|
DuPont submitted updated occupational blood monitoring information for Perfluorooctanoic Acid (PFOA) to the EPA, reporting serum sample results from Axys Analytical Services that corroborate previously reported levels, with PFOA concentrations ranging from 7.71 ng/mL to 2630 ng/mL and consistent results compared to Exygen Laboratories.
|
2006 |
AR226-3733
|
3Q2dLmy8VGLLaEavLZOoojm2a |
3 |
|
The document reports on a health study investigating self-reported medical conditions, including cancers, among employees at a 3M facility in Decatur, Alabama, potentially linked to exposure to perfluorooctanesulfonyl fluoride (POSF) and perfluorooctanesulfonate (PFOS).
|
2006 |
AR226-3732
|
pmv17Z5z2OGLanbK1w2xKXN7w |
26 |
|
DuPont submitted a document to the EPA containing analytical results for perfluorinated organics, specifically from a report by Axys Analytical Services requested by the Little Hocking Water Association, but DuPont does not verify the validity of the results.
|
2006 |
AR226-3581
|
L6R5g8vBoyXV2Ng1g93odkbw |
8 |
|
This document is a follow-up letter from DuPont to the EPA regarding an oral repeated dose toxicity study in rats and mice involving linear and branched forms of perfluorooctanoic acid (APFO).
|
2006 |
AR226-3582
|
0gobp9v493YxK520q7D8DmDpx |
2 |
|
This document is a report from Daikin America, Inc. submitted to the EPA detailing the material balance for Perfluorooctanoic Acid (PFOA) at their Decatur Plant for the year 2005, including a comparison to data from 2000.
|
2006 |
AR226-3730
|
QgbpqOx5Qw47NbrYLa7xLbbg4 |
2 |
|
The document discusses a submission by 3M to the EPA regarding additional information on a mortality study and subsequent health incidence study of workers at a perfluorooctanesulfonyl fluoride (POSF)-based fluorochemical manufacturing facility, highlighting findings related to bladder cancer and other health conditions reported by workers.
|
2006 |
AR226-3731
|
KRn2jeq9ZZoLOdMKKoxLJ2mBN |
2 |
|
DuPont submitted updated occupational blood monitoring information for perfluorooctanoic acid (PFOA) to the EPA, reporting that serum samples analyzed by Axys Analytical Services showed PFOA levels ranging from 7.71 ng/mL to 2630 ng/mL, which were consistent with previous findings from Exygen Laboratories.
|
2006 |
AR226-3733
|
ZBbxqGnkQZK0V2djyv38q037 |
3 |
|
This document is the final report for a developmental neurotoxicity and thyroid function study of MTDID 208, conducted by WIL Research Laboratories for 3M Corporation, which complied with EPA guidelines but noted some non-GLP conditions in specific analyses.
|
2006 |
AR226-3802
|
6w2BBkZzLR24Gb5jBQkbyMjB4 |
2200 |
|
The document contains analytical results for various perfluorinated compounds, including PFOA and PFOS, from samples collected at DuPont facilities, detailing recovery rates and concentrations detected in the samples.
|
2006 |
AR226-3734
|
Rad7znvGO2oBDp5aVzDMzQnwk |
4 |
|
The document is a final report on a health study investigating self-reported medical conditions, including cancers, among employees at a 3M facility in Decatur, Alabama, potentially linked to exposure to perfluorooctanesulfonyl fluoride (POSF) and perfluorooctanesulfonate (PFOS).
|
2006 |
AR226-3732
|
bbkoy23wXDBNvNe2N6yGx4xZ |
26 |
|
This document includes analytical reports from Axys Analytical Services detailing the analysis of serum samples for various perfluorinated compounds, specifically related to job number WG18498.
|
2006 |
AR226-3735
|
nkrLJR0eNNKNkoJpZeojy5YOm |
3 |
|
The document outlines preliminary protocols for a health study on the effects of exposure to C8 (PFOA) around the Washington Works plant, emphasizing the confidentiality of initial data received and cautioning against premature public dissemination of findings.
|
2006 |
AR226-3737
|
DGbVL1egRmgjNoLdJ8GeaXvbM |
1 |
|
DuPont provided preliminary partial non-occupational blood data on perfluorooctanoic acid (PFOA) collected from communities in West Virginia and Ohio to the EPA, noting that they do not have access to the complete dataset from Brookmar, which is conducting the study independently.
|
2006 |
AR226-3736
|
mqyJnYe0GokK0w3G0Gawz1gog |
3 |
|
The document presents statistical data on C8 (PFOA) blood levels among a community cohort in 2005, detailing demographics, body mass index, and distribution of C8 concentrations across different water districts.
|
2006 |
AR226-3738
|
jZxL0gOdZO2DdQ4OJg6pkEZk |
6 |
|
The document presents preliminary analyses of pregnancy outcomes among women, including miscarriage, stillbirth, and birth defects, in relation to exposure to perfluorinated compounds, specifically focusing on data from 18,276 women and estimating total pregnancy outcomes based on initial findings.
|
2006 |
AR226-3740
|
zbMmzDxZNQ6oED1z0wrEgwB6B |
3 |